@article{RichterHuettmannRekowskietal.2019,
  author    = {Richter, Julia and H{\"u}ttmann, Andreas and Rekowski, Jan and Schmitz, Christine and G{\"a}rtner, Selina and Rosenwald, Andreas and Hansmann, Martin-Leo and Hartmann, Sylvia and M{\"o}ller, Peter and Wacker, Hans-Heinrich and Feller, Alfred and Thorns, Christoph and M{\"u}ller, Stefan and D{\"u}hrsen, Ulrich and Klapper, Wolfram},
  title     = {Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome},
  series = {Blood Cancer Journal},
  volume    = {9},
  journal   = {Blood Cancer Journal},
  doi       = {10.1038/s41408-019-0230-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226185},
  pages     = {67},
  year      = {2019},
  abstract  = {No abstract available},
  language  = {en}
}
@phdthesis{Moeller2022,
  author    = {M{\"o}ller, Jan},
  title     = {Mechanisms and consequences of µ-opioid receptor dimerization},
  doi       = {10.25972/OPUS-21986},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-219862},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {One third of all market approved drugs target G protein coupled receptors (GPCRs), covering a highly diverse spectrum of indications reaching from acute anti-allergic treatment over bloodpressure regulation, Parkinson's disease, schizophrenia up to the treatment of severe pain. GPCRs are key signaling proteins that mostly function as monomers, but for several receptors constitutive dimer formation has been described and in some cases is essential for function. I have investigated this problem using the μ-opioid receptor (µOR) as a model system - based both on its pharmacological importance and on specific biochemical data suggesting that it may present a particularly intriguing case of mono- vs- dimerization. The µOR is the prime target for the treatment of severe pain. In its inactive conformation it crystallizes as homodimer when bound to the antagonist β- funaltrexamine (β-FNA), whereas the active, agonist-bound receptor crystallizes as a monomer. Using single-molecule microscopy combined with superresolution techniques on intact cells, I describe here a dynamic monomer-dimer equilibrium of µORs where dimer formation is driven by specific agonists. The agonist DAMGO, but not morphine, induces dimer formation in a process that correlates temporally and, in its agonist, and phosphorylation dependence with β-arrestin2 binding to the receptors. This dimerization is independent from but may precede µOR internalization. Furthermore, the results show that the μOR tends to stay, on the cell surface, within compartments defined by actin fibers and its mobility is modulated by receptor activation. These data suggest a new level of GPCR regulation that links receptor compartmentalization and dimer formation to specific agonists and their downstream signals.},
  subject      = {Opiatrezeptor},
  language  = {en}
}
@article{LopezKleinheinzAukemaetal.2019,
  author    = {L{\´o}pez, Cristina and Kleinheinz, Kortine and Aukema, Sietse M. and Rohde, Marius and Bernhart, Stephan H. and H{\"u}bschmann, Daniel and Wagener, Rabea and Toprak, Umut H. and Raimondi, Francesco and Kreuz, Markus and Waszak, Sebastian M. and Huang, Zhiqin and Sieverling, Lina and Paramasivam, Nagarajan and Seufert, Julian and Sungalee, Stephanie and Russell, Robert B. and Bausinger, Julia and Kretzmer, Helene and Ammerpohl, Ole and Bergmann, Anke K. and Binder, Hans and Borkhardt, Arndt and Brors, Benedikt and Claviez, Alexander and Doose, Gero and Feuerbach, Lars and Haake, Andrea and Hansmann, Martin-Leo and Hoell, Jessica and Hummel, Michael and Korbel, Jan O. and Lawerenz, Chris and Lenze, Dido and Radlwimmer, Bernhard and Richter, Julia and Rosenstiel, Philip and Rosenwald, Andreas and Schilhabel, Markus B. and Stein, Harald and Stilgenbauer, Stephan and Stadler, Peter F. and Szczepanowski, Monika and Weniger, Marc A. and Zapatka, Marc and Eils, Roland and Lichter, Peter and Loeffler, Markus and M{\"o}ller, Peter and Tr{\"u}mper, Lorenz and Klapper, Wolfram and Hoffmann, Steve and K{\"u}ppers, Ralf and Burkhardt, Birgit and Schlesner, Matthias and Siebert, Reiner},
  title     = {Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma},
  series = {Nature Communications},
  volume    = {10},
  journal   = {Nature Communications},
  organization    = {ICGC MMML-Seq Consortium},
  doi       = {10.1038/s41467-019-08578-3},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-237281},
  year      = {2019},
  abstract  = {Burkitt lymphoma (BL) is the most common B-cell lymphoma in children. Within the International Cancer Genome Consortium (ICGC), we performed whole genome and transcriptome sequencing of 39 sporadic BL. Here, we unravel interaction of structural, mutational, and transcriptional changes, which contribute to MYC oncogene dysregulation together with the pathognomonic IG-MYC translocation. Moreover, by mapping IGH translocation breakpoints, we provide evidence that the precursor of at least a subset of BL is a B-cell poised to express IGHA. We describe the landscape of mutations, structural variants, and mutational processes, and identified a series of driver genes in the pathogenesis of BL, which can be targeted by various mechanisms, including IG-non MYC translocations, germline and somatic mutations, fusion transcripts, and alternative splicing.},
  language  = {en}
}
@article{MeralProvasiPradaGraciaetal.2018,
  author    = {Meral, Derya and Provasi, Davide and Prada-Gracia, Diego and M{\"o}ller, Jan and Marino, Kristen and Lohse, Martin J. and Filizola, Marta},
  title     = {Molecular details of dimerization kinetics reveal negligible populations of transient µ-opioid receptor homodimers at physiological concentrations},
  series = {Scientific Reports},
  volume    = {8},
  journal   = {Scientific Reports},
  doi       = {10.1038/s41598-018-26070-8},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-223995},
  year      = {2018},
  abstract  = {Various experimental and computational techniques have been employed over the past decade to provide structural and thermodynamic insights into G Protein-Coupled Receptor (GPCR) dimerization. Here, we use multiple microsecond-long, coarse-grained, biased and unbiased molecular dynamics simulations (a total of ~4 milliseconds) combined with multi-ensemble Markov state models to elucidate the kinetics of homodimerization of a prototypic GPCR, the µ-opioid receptor (MOR), embedded in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/cholesterol lipid bilayer. Analysis of these computations identifies kinetically distinct macrostates comprising several different short-lived dimeric configurations of either inactive or activated MOR. Calculated kinetic rates and fractions of dimers at different MOR concentrations suggest a negligible population of MOR homodimers at physiological concentrations, which is supported by acceptor photobleaching fluorescence resonance energy transfer (FRET) experiments. This study provides a rigorous, quantitative explanation for some conflicting experimental data on GPCR oligomerization.},
  language  = {en}
}